### Indication
Other specified malignant neoplasms of the ovary  
**ICD11 code:** 2D23.Y

### INN
Ifosfamide

### Medicine type
Chemical agent

### List type
Complementary

### Formulations
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

### EML status history
- First added in 2009 (TRS 958)
- Changed in 2015 (TRS 994)

### Sex
All

### Age
Also recommended for children

### Therapeutic alternatives
The recommendation is for this specific medicine

### Patent information
Patents have expired in most jurisdictions  
[Read more about patents.](#)

### Tags
- Cancer

### Wikipedia
- [Ifosfamide](#)

### DrugBank
- [Ifosfamide](#)

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for ovarian germ cell tumour was specifically endorsed. Additionally, ifosfamide was included on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ovarian germ cell tumour is attached.

[Expert Committee report](#)